Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 9/20 | 0.64 |
| ▸ | DRD2 | P14416 | 5/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.54 |
| ▸ | HTR7 | P34969 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6593331 | 0.97 | DRD2 (0.60) | HTR1ADRD2SLC6A4HTR7KCNH2 | |
| SCHEMBL6592113 | 0.94 | DRD2 (0.59) | HTR1ADRD2SLC6A4HTR7KCNH2 | |
| SCHEMBL6593130 | 0.93 | DRD2 (0.67) | HTR1ADRD2SLC6A4HTR7KCNH2 | |
| SCHEMBL6582347 | 0.90 | DRD2 (0.58) | HTR1ADRD2SLC6A4HTR7KCNH2 | |
| SCHEMBL6593377 | 0.89 | HTR1A (0.70) | HTR1ADRD2SLC6A4HTR7KCNH2 | |
| SCHEMBL6591742 | 0.88 | HTR1A (0.59) | HTR1ADRD2SLC6A4HTR7KCNH2 | |
| SCHEMBL6589609 | 0.88 | DRD2 (0.63) | HTR1ADRD2SLC6A4HTR7KCNH2 | |
| SCHEMBL6589620 | 0.88 | HTR1A (0.57) | HTR1ADRD2SLC6A4HTR7KCNH2 | |
| SCHEMBL6594073 | 0.88 | DRD2 (0.63) | HTR1ADRD2SLC6A4HTR7KCNH2 | |
| SCHEMBL6592081 | 0.88 | DRD2 (0.63) | HTR1ADRD2SLC6A4HTR7KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1246816-B1 | SUBSTITUTED PHENYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND USE | LUNDBECK & CO AS H (DK) | 2004-03-17 | — | — | EP | claimed |
| US-6699864-B2 | SERATONIN REUPTAKE INHIBITORS POTENTLY BINDING TO THE 5-HT1A RECEPTOR, DOPAMINERGIC AGENTS; ANTIDEPRESSANTS, PSYCHOSIS, ANXIOLYTIC AND ANTIISCHEMIC AGENTS; PANIC ORDER; OBSESSIVE COMPULSIVE DISORDER, IMPULSE CONTROL DISORDER, ALCOHOL ABUSE | H. LUNDBECK A/S (DK) | 2004-03-02 | — | — | US | claimed |
| US-20030125320-A1 | Substituted phenyl-piperazine derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2003-07-03 | — | — | US | claimed |
| WO-2001049678-A9 | SUBSTITUTED PHENYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND USE | LUNDBECK & CO AS H (DK) | 2002-10-10 | — | — | WO | claimed |
| EP-1246816-A1 | SUBSTITUTED PHENYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND USE | H. Lundbeck A/S (DK) | 2002-10-09 | — | — | EP | claimed |
| WO-2001049678-A1 | SUBSTITUTED PHENYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND USE | H. LUNDBECK A/S (DK) | 2001-07-12 | — | — | WO | claimed |
| EP-1246816-B1 | SUBSTITUTED PHENYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND USE | LUNDBECK & CO AS H (DK) | 2004-03-17 | — | — | EP | disclosed |
| US-6699864-B2 | SERATONIN REUPTAKE INHIBITORS POTENTLY BINDING TO THE 5-HT1A RECEPTOR, DOPAMINERGIC AGENTS; ANTIDEPRESSANTS, PSYCHOSIS, ANXIOLYTIC AND ANTIISCHEMIC AGENTS; PANIC ORDER; OBSESSIVE COMPULSIVE DISORDER, IMPULSE CONTROL DISORDER, ALCOHOL ABUSE | H. LUNDBECK A/S (DK) | 2004-03-02 | — | — | US | disclosed |
| US-20030125320-A1 | Substituted phenyl-piperazine derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2003-07-03 | — | — | US | disclosed |
| US-20030040639-A1 | Method for the preparation of substituted benzene derivatives | H. LUNDBECK A/S (DK) | 2003-02-27 | — | — | US | disclosed |
| WO-2001049678-A9 | SUBSTITUTED PHENYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND USE | LUNDBECK & CO AS H (DK) | 2002-10-10 | — | — | WO | disclosed |
| EP-1246816-A1 | SUBSTITUTED PHENYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND USE | H. Lundbeck A/S (DK) | 2002-10-09 | — | — | EP | disclosed |
| WO-2001049678-A1 | SUBSTITUTED PHENYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND USE | H. LUNDBECK A/S (DK) | 2001-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125320-A1 | Substituted phenyl-piperazine derivatives, their preparation and use | HTR5A, HTR1A, HTR1D | HTR1A 2/4885DRD2 56/4885SLC6A4 100/4885 |
| US-20030040639-A1 | Method for the preparation of substituted benzene derivatives | SCLY, CBR3, TST | HTR1A 3727/4885DRD2 1490/4885SLC6A4 1494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.